JP2022119854A5 - - Google Patents

Download PDF

Info

Publication number
JP2022119854A5
JP2022119854A5 JP2022081779A JP2022081779A JP2022119854A5 JP 2022119854 A5 JP2022119854 A5 JP 2022119854A5 JP 2022081779 A JP2022081779 A JP 2022081779A JP 2022081779 A JP2022081779 A JP 2022081779A JP 2022119854 A5 JP2022119854 A5 JP 2022119854A5
Authority
JP
Japan
Prior art keywords
formulation
concentration
liquid formulation
sequence
lyophilized pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022081779A
Other languages
English (en)
Japanese (ja)
Other versions
JP7603201B2 (ja
JP2022119854A (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/065819 external-priority patent/WO2018002031A1/en
Application filed filed Critical
Publication of JP2022119854A publication Critical patent/JP2022119854A/ja
Publication of JP2022119854A5 publication Critical patent/JP2022119854A5/ja
Priority to JP2024083988A priority Critical patent/JP2024109816A/ja
Application granted granted Critical
Publication of JP7603201B2 publication Critical patent/JP7603201B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022081779A 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤 Active JP7603201B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083988A JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16176322.2 2016-06-27
EP16176322 2016-06-27
PCT/EP2017/065819 WO2018002031A1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations
JP2018567742A JP2019524671A (ja) 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018567742A Division JP2019524671A (ja) 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083988A Division JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Publications (3)

Publication Number Publication Date
JP2022119854A JP2022119854A (ja) 2022-08-17
JP2022119854A5 true JP2022119854A5 (enExample) 2023-04-10
JP7603201B2 JP7603201B2 (ja) 2024-12-20

Family

ID=56368805

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018567742A Pending JP2019524671A (ja) 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤
JP2022081779A Active JP7603201B2 (ja) 2016-06-27 2022-05-18 抗ｃｄ１９抗体製剤
JP2024083988A Pending JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018567742A Pending JP2019524671A (ja) 2016-06-27 2017-06-27 抗ｃｄ１９抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083988A Pending JP2024109816A (ja) 2016-06-27 2024-05-23 抗ｃｄ１９抗体製剤

Country Status (26)

Country Link
US (2) US11352423B2 (enExample)
EP (2) EP3909985A1 (enExample)
JP (3) JP2019524671A (enExample)
KR (2) KR102533875B1 (enExample)
CN (2) CN115998859A (enExample)
AU (2) AU2017289085B2 (enExample)
CA (1) CA3029137A1 (enExample)
CY (1) CY1124521T1 (enExample)
DK (1) DK3475303T3 (enExample)
ES (1) ES2874640T3 (enExample)
HR (1) HRP20210945T1 (enExample)
HU (1) HUE054296T2 (enExample)
IL (1) IL263764B2 (enExample)
LT (1) LT3475303T (enExample)
MA (1) MA45450B1 (enExample)
MD (1) MD3475303T2 (enExample)
MX (1) MX2018016362A (enExample)
PL (1) PL3475303T3 (enExample)
PT (1) PT3475303T (enExample)
RS (1) RS62035B1 (enExample)
RU (1) RU2748024C2 (enExample)
SG (2) SG10201912369QA (enExample)
SI (1) SI3475303T1 (enExample)
SM (1) SMT202100317T1 (enExample)
WO (1) WO2018002031A1 (enExample)
ZA (1) ZA201900483B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
AU2020372646A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
JP2023530499A (ja) 2020-06-22 2023-07-18 モルフォシス・アーゲー 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
AU2023264582A1 (en) * 2022-05-03 2024-11-21 Incyte Corporation Methods for treating lymphoma
EP4572756A1 (en) 2022-08-17 2025-06-25 Incyte Corporation Therapy comprising anti-cd19 antibody and ezh2 modulators
IL322510A (en) * 2023-03-02 2025-10-01 Novetide Ltd Method for preparing GLP-1 peptides with controlled particle size
CN120754244B (zh) * 2025-09-10 2025-12-12 江苏豪森药业集团有限公司 一种含抗cd19抗体的药物组合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
JP2012519712A (ja) * 2009-03-06 2012-08-30 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体製剤
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
RU2707092C2 (ru) 2013-03-13 2019-11-22 Дженентек, Инк. Составы со сниженным окислением
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
LT3049441T (lt) 2013-09-27 2020-02-10 F. Hoffmann-La Roche Ag Anti-pdl1 antikūnų kompozicija
JP6590803B2 (ja) * 2013-11-21 2019-10-16 ゲンマブ エー／エス 抗体−薬物コンジュゲート凍結乾燥製剤
CA2942150A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Similar Documents

Publication Publication Date Title
JP2022119854A5 (enExample)
JP2024109816A5 (enExample)
JP2020158505A5 (enExample)
JP2022036932A5 (enExample)
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
JP2020518599A5 (enExample)
RU2486198C2 (ru) Антиген, ассоциированный с ревматоидным артритом
JP2023093495A5 (enExample)
JP2020509027A5 (enExample)
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
JP2013500947A5 (enExample)
RU2017143166A (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
RU2019113370A (ru) Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения
JP2023055904A5 (enExample)
PE20201503A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables
RU2014103492A (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
CL2024000232A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
JP2019519770A5 (enExample)
JP2025090691A5 (enExample)
FI3630177T3 (fi) Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
CN118234749A (zh) 用于预防异种移植中的移植物排斥的方法
RU2008151516A (ru) СПОСОБ УВЕЛИЧЕНИЯ БИОЛОГИЧЕСКОЙ АКТИВНОСТИ ОЧИЩЕННОГО БЕЛКА HspE7
AR083338A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r)